The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia
|
|---|---|
| Published in |
Frontiers in oncology, June 2018
|
| DOI | 10.3389/fonc.2018.00229 |
| Pubmed ID | |
| Authors |
Emanuela Rosati, Stefano Baldoni, Filomena De Falco, Beatrice Del Papa, Erica Dorillo, Chiara Rompietti, Elisa Albi, Franca Falzetti, Mauro Di Ianni, Paolo Sportoletti |
| Abstract |
Chronic lymphocytic leukemia (CLL) is an incurable B-cell neoplasm characterized by highly variable clinical outcomes. In recent years, genomic and molecular studies revealed a remarkable heterogeneity in CLL, which mirrored the clinical diversity of this disease. These studies profoundly enhanced our understanding of leukemia cell biology and led to the identification of new biomarkers with potential prognostic and therapeutic significance. Accumulating evidence indicates a key role of deregulated NOTCH1 signaling and NOTCH1 mutations in CLL. This review highlights recent discoveries that improve our understanding of the pathophysiological NOTCH1 signaling in CLL and the clinical impact of NOTCH1 mutations in retrospective and prospective trials. In addition, we discuss the rationale for a therapeutic strategy aiming at inhibiting NOTCH1 signaling in CLL, along with an overview on the currently available NOTCH1-directed approaches. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 112 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 15% |
| Researcher | 15 | 13% |
| Student > Master | 15 | 13% |
| Other | 7 | 6% |
| Student > Ph. D. Student | 7 | 6% |
| Other | 18 | 16% |
| Unknown | 33 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 37 | 33% |
| Medicine and Dentistry | 22 | 20% |
| Agricultural and Biological Sciences | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Immunology and Microbiology | 3 | 3% |
| Other | 6 | 5% |
| Unknown | 35 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2021.
All research outputs
#19,951,180
of 25,385,509 outputs
Outputs from Frontiers in oncology
#9,328
of 22,428 outputs
Outputs of similar age
#251,766
of 342,755 outputs
Outputs of similar age from Frontiers in oncology
#92
of 150 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,428 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,755 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 150 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.